EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS ‐mediated mechanisms

Xining Zhang, Xingming Liao, Min Wang, Jiao Liu, Jiaxin Han, Dong An, Tiezheng Zheng, Xuefei Wang, Hailing Cheng iD, Pixu Liu

Cancer Science · 2024-04 · 115 (4) · 1170-1183

DOI: 10.1111/cas.16085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 29.01.2024. Verfasst von Xining Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Dalian Key Laboratory of Molecular Targeted Cancer Therapy, The Second Hospital of Dalian Medical University, Dalian Medical Univer…. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Innovation Fund of Dalian Department of Science and Technology, Scientific Research Fund of Liaoning Provincial Department of Education, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum‐based therapies have revolutionized the treatment of high‐grade serous ovarian cancer (HGSOC). However, high rates of disease recurrence and progression remain a major clinical concern. Impaired mitochondrial function and dysregulated reactive oxygen species (ROS), hallmarks of cancer, hold potential as therapeutic targets for selectively sensitizing cisplatin treatment. Here, we uncover an oncogenic role of the palmitoyltransferase ZDHHC12 in regulating mitochondrial function and ROS homeostasis in HGSOC cells. Analysis of The Cancer Genome Atlas (TCGA) ovarian cancer data revealed significantly elevated ZDHHC12 expression, demonstrating the strongest positive association with ROS pathways among all ZDHHC enzymes. Transcriptomic analysis of independent ovarian cancer datasets and the SNU119 cell model corroborated this association, highlighting a strong link between ZDHHC12 expression and signature pathways involving mitochondrial oxidative metabolism and ROS regulation. Knockdown of ZDHHC12 disrupted this association, leading to increased cellular complexity, ATP levels, mitochondrial activity, and both mitochondrial and cellular ROS. This dysregulation, achieved by the siRNA knockdown of ZDHHC12 or treatment with the general palmitoylation inhibitor 2BP or the fatty acid synthase inhibitor C75, significantly enhanced cisplatin cytotoxicity in 2D and 3D spheroid models of HGSOC through ROS‐mediated mechanisms. Markedly, ZDHHC12 inhibition significantly augmented the anti‐tumor activity of cisplatin in an ovarian cancer xenograft tumor model, as well as in an ascites‐derived organoid line of platinum‐resistant ovarian cancer. Our data suggest the potential of ZDHHC12 as a promising target to improve the outcome of HGSOCs in response to platinum‐based chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinOvarian NeoplasmsHumansFemaleReactive Oxygen SpeciesDrug Resistance, NeoplasmNeoplasm Recurrence, LocalCarcinoma, Ovarian EpithelialCell Line, Tumor

Stichwörter der Autor:innen

HGSOCZDHHC12cisplatinmitochondrial ROSprotein palmitoylation

Substanzen

CisplatinReactive Oxygen Species

Autor:innen und Institutionen

  • Cancer Institute, Dalian Key Laboratory of Molecular Targeted Cancer Therapy, The Second Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.

ORCID-Profile: Hailing Cheng

Förderung

  • Science and Technology Innovation Fund of Dalian Department of Science and Technology
  • Scientific Research Fund of Liaoning Provincial Department of Education
  • National Natural Science Foundation of China
  • Liaoning Revitalization Talents Program

Zitieren

APA

Zhang, X., Liao, X., Wang, M., Liu, J., Han, J., An, D., Zheng, T., Wang, X., Cheng, H., & Liu, P. (2024). Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS ‐mediated mechanisms. Cancer Science, 115(4), 1170-1183. https://doi.org/10.1111/cas.16085

Vancouver

Zhang X, Liao X, Wang M, Liu J, Han J, An D, et al. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS ‐mediated mechanisms. Cancer Science. 2024;115(4):1170-1183. doi:10.1111/cas.16085

BibTeX
@article{Zhang2024,
  author = {Zhang, Xining and Liao, Xingming and Wang, Min and Liu, Jiao and Han, Jiaxin and An, Dong and Zheng, Tiezheng and Wang, Xuefei and Cheng, Hailing and Liu, Pixu},
  title = {Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS ‐mediated mechanisms},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {4},
  pages = {1170--1183},
  doi = {10.1111/cas.16085}
}
Kostenlos starten →